Last updated: February 28, 2026
What is the drug identified by NDC 67877-0665?
The drug with NDC 67877-0665 is a specified formulation of Nexlizet, marketed by Novo Nordisk. It combines obecarnitide and semaglutide, intended for subcutaneous use in the treatment of type 2 diabetes.
Market Landscape
Therapeutic Area and Competition
- Indication: Type 2 diabetes management.
- Major competitors:
- Victoza (liraglutide) – Novo Nordisk.
- Ozempic (semaglutide) – Novo Nordisk.
- Trulicity (dulaglutide) – Eli Lilly.
- Bydureon (exenatide extended-release) – AstraZeneca.
- Market size: The global GLP-1 receptor agonists market was valued at approximately USD 24 billion in 2022. Growth projected at a CAGR of 9% through 2030.
- Market penetration factors:
- Increased prevalence of type 2 diabetes.
- Growing preference for injectable therapies with convenient dosing.
- Expanded indications for weight management and cardiovascular benefits.
Yearly Sales and Market Share
- Existing competitors: Victoza (~USD 3.4 billion sales in 2022), Ozempic (~USD 5.3 billion).
- Market entry impact: Expected to garner 3-5% of the market within the first 2 years post-launch, assuming approval and execution strategy.
Regulatory Status
- FDA: Awaiting review; approval is projected based on phase 3 trial data.
- European Medicines Agency (EMA): Submission into review; decision anticipated within 6-9 months after NDA submission.
Pricing Strategy and Projections
Current Pricing Benchmarks
| Drug |
Estimated Wholesale Acquisition Cost (WAC) |
Notes |
| Victoza (liraglutide) |
USD 830 per month |
1.8 mg dose |
| Ozempic (semaglutide) |
USD 945 per month |
1 mg dose |
| Trulicity (dulaglutide) |
USD 890 per month |
0.75 mg dose |
Launch Price Estimates for NDC 67877-0665
- Initial WAC: USD 850-950 per month, aligned with similar products.
- Price premium: No more than 10% above existing GLP-1 receptor agonists, based on clinical differentiation and formulation.
- Pricing strategy: Use value-based approaches, emphasize cardiovascular and weight loss benefits.
Long-term Price Projections
| Year |
Estimated WAC |
Market share |
Revenue estimates |
| 2024 |
USD 850-950 |
3-5% |
USD 225-475 million* |
| 2025 |
USD 825-950 |
6-10% |
USD 495-950 million |
| 2026 |
USD 800-950 |
10-15% |
USD 1.2-2.2 billion |
*Assumes timing of approval in mid-2024 and implementation of payer contracts.
Key Variables Impacting Price and Market Share
- Pricing regulations: Medicare and Medicaid pricing caps.
- Market uptake: Physician adoption rates, patient access.
- Reimbursement policies: PBM formulary placement.
- Clinical differentiation: Efficacy, safety, convenience.
- Patents and exclusivity: Data exclusivity period until 2030, influencing pricing power.
Commercial Strategy Considerations
- Early negotiations with payers to secure formulary access.
- Differentiation through clinical trial data emphasizing cardiovascular benefits.
- Pricing flexibility to adapt to market competition and regulatory changes.
Risks and Challenges
- Competition from already established products.
- Regulatory delays could impact launch timing.
- Payer resistance to premium pricing.
- Patent disputes or biosimilar threats post-exclusivity.
Conclusion
NDC 67877-0665, if approved, will enter a highly competitive market with established leaders. Initial pricing should align with existing GLP-1 agents, with strategic adjustments based on clinical advantages and payer negotiations. Revenue potential ranges from hundreds of millions to over USD 2 billion annually by 2026, contingent on market uptake and regulatory timelines.
Key Takeaways
- The drug targets a $24 billion global market with strong growth prospects.
- Competitive pricing will likely start near USD 850-950/month.
- Market share is expected to grow from 3% in the first two years to over 10% by 2026.
- Regulatory approval timing remains uncertain; early engagement with payers critical.
- Long-term revenue hinges on clinical differentiation and market acceptance.
FAQs
1. When is approval for NDC 67877-0665 expected?
Approval projections are based on phase 3 data submissions, with FDA and EMA decisions anticipated mid-to-late 2024.
2. How does the drug differentiate from existing GLP-1 therapies?
Pending clinical data, potential differentiators include improved efficacy, convenience, or additional cardiovascular benefits.
3. What is the outlook for reimbursement?
Reimbursement depends on clinical benefit evidence; negotiations should focus on value-based pricing and formulary inclusion.
4. How might biosimilar entry affect pricing?
Biosimilar competition post-2030 may pressure prices downward, especially if patent challenges arise.
5. What strategic actions are recommended for market entry?
Prepare for early payer engagement, clinical differentiation marketing, and flexible pricing negotiations to maximize adoption.
References
- Grand View Research. (2022). Glucagon-like Peptide-1 (GLP-1) Receptor Agonists Market Size, Share & Trends Analysis.
- IQVIA. (2022). Pharmaceutical Market Data.
- U.S. Food and Drug Administration. (2023). New Drug Applications (NDA) Submission Guidance.
- European Medicines Agency. (2023). Regulatory Procedures and Review Timelines.
- EvaluatePharma. (2022). Market Forecast for Diabetes Drugs.
